x
Filter:
Filters applied
- Accelerated Communications
- CRCRemove CRC filter
Publication Date
Please choose a date range between 2022 and 2022.
Author
- Ahmed, Yashi1
- Bahudhanapati, Harinath1
- Chandrasekera, Pathirennehelage1
- Chen, Wei-Chih1
- Christian, Laura1
- Hong, Charles C1
- Kulkarni, Pallavi1
- Lee, Ethan1
- Li, Bin1
- Li, Jiejing1
- Liu, Jun1
- Lu, Congyu1
- Nayak, Anmada1
- Neitzel, Leif R1
- Perfetto, Mark1
- Robbins, David J1
- Shen, Chen1
- Wei, Shuo1
- Williams, Charles H1
- Yang, Fan1
- Yien, Yvette Y1
- Yu, Chundong1
- Zhuo, Minghui1
JBC Communications
2 Results
- Accelerated CommunicationOpen Access
Metalloprotease ADAM9 cleaves ephrin-B ligands and differentially regulates Wnt and mTOR signaling downstream of Akt kinase in colorectal cancer cells
Journal of Biological ChemistryVol. 298Issue 8102225Published online: June 30, 2022- Pathirennehelage Chandrasekera
- Mark Perfetto
- Congyu Lu
- Minghui Zhuo
- Harinath Bahudhanapati
- Jiejing Li
- and others
Cited in Scopus: 1Ephrin-B signaling has been implicated in many normal and pathological processes, including neural crest development and tumor metastasis. We showed previously that proteolysis of ephrin-B ligands by the disintegrin metalloprotease ADAM13 is necessary for canonical Wnt signal activation and neural crest induction in Xenopus, but it was unclear if these mechanisms are conserved in mammals. Here, we report that mammalian ADAM9 cleaves ephrin-B1 and ephrin-B2 and can substitute for Xenopus ADAM13 to induce the neural crest. - Accelerated Communication Editors' PickOpen Access
The Casein kinase 1α agonist pyrvinium attenuates Wnt-mediated CK1α degradation via interaction with the E3 ubiquitin ligase component Cereblon
Journal of Biological ChemistryVol. 298Issue 8102227Published online: June 30, 2022- Chen Shen
- Anmada Nayak
- Leif R. Neitzel
- Fan Yang
- Bin Li
- Charles H. Williams
- and others
Cited in Scopus: 1The Cullin-RING ligase 4 E3 ubiquitin ligase component Cereblon (CRBN) is a well-established target for a class of small molecules termed immunomodulatory drugs (IMiDs). These drugs drive CRBN to modulate the degradation of a number of neosubstrates required for the growth of multiple cancers. Whereas the mechanism underlying the activation of CRBN by IMiDs is well described, the normal physiological regulation of CRBN is poorly understood. We recently showed that CRBN is activated following exposure to Wnt ligands and subsequently mediates the degradation of a subset of physiological substrates.